Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis

Myocardial Infarction Clinical Trial

Official title:

Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03377465
• Other study ID #: 01122017
• Status: Completed
• Phase: N/A
• First received: December 5, 2017
• Last updated: December 13, 2017
• Start date: November 15, 2016
• Est. completion date: December 5, 2017

Study information

• Verified date: December 2017
• Source: Medical Universtity of Lodz
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A stroke is the second cause of deaths after heart attack, one of the most important causes of malfunction as far as adults are concerned and the second as for the frequency cause of dementia. In spite of a possibility of the therapy of stroke ( tissue plasminogen activator) and recognized most of risk factors there is expected that incidence rate on stroke connected with ageing of the society will be growing. It will cause medical and social consequences.

There are many of potential causes of cardiac strokes, which are not entirely examined.

More over many cryptogenic strokes are presumed to have an embolic etiology, and the frequent cause of these kind of strokes at young age is probably the mechanism of paradoxical embolism through patent foramen ovale.

As far as the investigators are concerned, at present there is lack of any recommendations for these scientific hypothesis.

Description:

A stroke is the second cause of deaths after heart attack, one of the most important causes of malfunction as far as adults are concerned and the second as for the frequency cause of dementia. In spite of a possibility of the therapy of stroke ( tissue plasminogen activator) and recognized most of risk factors there is expected that incidence rate on stroke connected with ageing of the society will be growing. It will cause medical and social consequences.

The risk factors of stroke can be divided into alterable and not alterable. Importantly, the not alterable factors are: age, sex, race and genetic factors. After the age of 55 the risk of stroke grows twice in every decade of life. Moreover, it was alleged that incidence rate on stroke is more frequent at women than at men. At the black race the incidence rate on stroke is twice more frequent than at white race.

Well- known are also genetic syndromes connected with strokes like s. MELAS or CADASIL.

Well- known alterable factors are:

• hypertension

• coronary disease

• atrial fibrillation

• hypercholesterolemia

• diabetes

• nicotinism

• blood clotting disorder

• alcoholism

• TIA (transient ischemic attack) or previous former stroke

• asymptomatic stenosis of internal carotid artery

Cardiogenic stroke is a stroke caused by embolic material, which was created in cardiac cavities or on cardiac valves. They comprised 11% of all strokes and 25% of ischemic strokes. Additionally, among patients over 80 years old cardiac causes are responsible for even 40% of all ischemic strokes and half of cardiogenic strokes is caused of atrial fibrillation. Among young people (below 45 years old) about 50% of strokes are cardiogenic and are connected with paradoxical embolism at patients with patent foramen ovale.

Furthermore, cardiac- brain embolism is a result of:

• structural defect of cavities and valves of heart

• arrhythmia

• disturbances of movability of walls of the heart and function of endocardium which leads to increased risk of the risk of parietal thrombus

• cardiac insufficiency

There are many of potential causes of cardiac strokes, which are not entirely examined as for example:

• small pockets of intra- atrial septum

• structures in dextral atrium like Eustachian valve or Chiari network

• there is also a theory that even enlargement of left atrium may be the cause of brain stroke

• aneurysm of intra- atrial septum.

As far as the investigators are concerned, at present there is lack of any recommendations for these scientific hypothesis.

Available data suggest that in the comparison with atherosclerosis and lacunar strokes cardiogenic strokes characterize with high mortality ranging of 27%. Also the risk of relapse is higher than in strokes of other etiology.

Nevertheless, unfortunately, in spite of wide diagnostics at about 25-30% of patients with ischemic stroke the cause is unknown. This kind of stroke is called cryptogenic stroke or stroke with undefined etiology.

They constitute almost half of all ischemic stroke at young patients (below 55 years old). Many cryptogenic strokes are presumed to have an embolic etiology, and the frequent cause of these kind of strokes at young age is probably the mechanism of paradoxical embolism through patent foramen ovale.

To conclude, currently there aren't researches defining recommendations for long- lasting treatment patients with rare causes of strokes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 5, 2017
• Est. primary completion date: November 30, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• stroke of undetermined cause

Exclusion Criteria:

• unstable hypertension

• atrial fibrillation

• hyperthyroidism hard

• pregnancy and breastfeeding

• dialysis

• cancer

• autoimmunologic disease

• active infection

• incapable of giving agreement

Related Conditions & MeSH terms

• Atrial Fibrillation
• Atrial Fibrillation and Flutter
• Atrial Flutter
• Cardiac Tumor
• Cerebral Infarction
• Embolic Stroke of Undetermined Source
• Endocarditis
• Foramen Ovale, Patent
• Infarction
• Ischemia
• Ischemic Stroke
• Myocardial Infarction
• Patent Foramen Ovale
• Stroke

Intervention

Diagnostic Test:
• ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Medical Universtity of Lodz

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	physiological parameter	CRP (C reactive protein)	24 months
Primary	physiological parameter	IL-6 (interleukin 6)	24 months
Primary	physiological parameter	ADMA (asymmetric dimethylarginine)	24 months
Primary	physiological parameter	NTproB (N-terminal pro b-type natriuretic peptide)	24 months
Primary	physiological parameter	Adiponectin	24 months
Primary	physiological parameter	Leptine	24 months
Primary	physiological parameter	Resistin	24 months
Primary	physiological parameter	Syndecan	24 months